BIOENSIS Oncolytic Virus tools can be used for efficacy evaluation in 2D and 3D micro-tissues and include immune-cell killing, cell proliferation and phagocytosis assays,
Cell proliferation assays offers a systematic approach to evaluate therapeutic efficacy and biomarker associations across a diverse panel of cancer cell lines. Utilizing advanced 2D and 3D culture systems grown under physiologically relevant conditions, our platform better predicts in vivo activity. This enables confident selection of the most promising oncolytic virus candidates, helping to minimize costly false starts and accelerate the path to clinical development.
BIOENSIS’ Cell invasion/migration assays are designed to assess compound activity in key cancer processes such as tumor initiation, progression, metastasis, and tissue remodeling. These assays quantitatively measure a compound’s ability to inhibit invasive cancer and endothelial cell movement across basement membranes.
Immune-cell killing assays. These assays evaluate the capacity of therapeutic antibodies to activate T cells and NK cells to induce targeted cytotoxicity against tumor cells, providing insight into immune-mediated killing mechanisms.
Phagocytosis assays. Our ADCP assays assess the ability of monocyte-derived macrophages to eliminate tumor cells via antibody-mediated phagocytosis, offering a critical dimension in understanding immune effector function.
Please contact us to discuss your study requirements and an up to date list of available cell lines info@bioensis.com
